Bristol-Myers Squibb vs Tata Motors: Revenue, Profit and Business Model
Bristol-Myers Squibb reported $48.2B of revenue in FY2025 and $7.1B of net income. Tata Motors reported ~$9.7B of revenue in FY2026 and ~$351.5M of net income.
Latest financial snapshot
Bristol-Myers Squibb
- Latest revenue
- $48.2B (FY2025)
- Net income
- $7.1B
- Net margin
- 14.6%
- Revenue growth
- +10.6% a year, FY2016–FY2025
Tata Motors
- Latest revenue
- ~$9.7B (FY2026)
- Net income
- ~$351.5M
- Net margin
- 3.6%
- Revenue growth
- +3.2% a year, FY2024–FY2026
Financial summary
Bristol-Myers Squibb
Revenue grew from $19.4 billion in 2016 to $42.5 billion in 2020 as Celgene's sales were added, and has stayed between $45.0 billion and $48.3 billion since 2021. Net earnings are far less stable because BMS expenses acquired in-process R&D: the $11.4 billion MyoKardia charge produced a $9.0 billion net loss in 2020, and the Karuna charge produced an $8.9 billion loss in 2024. Cash generation is steadier, with free cash flow of about $12.8 billion in 2025. That cash funds a dividend raised for a 17th straight year in February 2026, to $0.63 a quarter, and debt reduction, from $51.2 billion at the end of 2024 to $47.2 billion a year later. On July 30, 2026 BMS raised its 2026 revenue guidance to $49.0 to $50.0 billion, from $46.0 to $47.5 billion, after second-quarter revenue rose 6 percent to $12.97 billion.
Tata Motors
The post-demerger Tata Motors Limited reported FY2026 (year to March 31, 2026) revenue from operations of ~$9.73B (INR83,855 Cr), up 44% from ~$6.75B (INR58,217 Cr), as wholesales rose 14% to about 428,000 units. The jump partly reflects the changed perimeter after the demerger, so it is not a clean like-for-like growth rate. Profit for the year fell 5.2% to ~$351M (INR3,030 Cr), weighed by one-time demerger costs (about $111M (INR960 Cr) in Q3) and new labour-code charges. Momentum carried into Q1 FY2027: revenue rose about 20% to ~$2.39B (INR20,576 Cr) and attributable profit rose 83% to ~$297M (INR2,560 Cr), helped by a one-time gain linked to Tata Capital, while commodity costs squeezed margins.
Revenue and profit by year
Bristol-Myers Squibb
| Year | Revenue | Net income | Margin | Growth | Source |
|---|---|---|---|---|---|
| FY2025 | $48.2B | $7.1B | 14.6% | -0.2% | Source |
| FY2024 | $48.3B | -$8.9B | -18.5% | +7.3% | Source |
| FY2023 | $45B | $8B | 17.8% | -2.5% | Source |
| FY2022 | $46.2B | $6.3B | 13.7% | -0.5% | Source |
| FY2021 | $46.4B | $7B | 15.1% | +9.1% | Source |
| FY2020 | $42.5B | -$9B | -21.2% | +62.6% | Source |
| FY2019 | $26.1B | $3.4B | 13.2% | +15.9% | Source |
| FY2018 | $22.6B | $4.9B | 21.8% | +8.6% | Source |
| FY2017 | $20.8B | $1B | 4.8% | +6.9% | Source |
| FY2016 | $19.4B | $4.5B | 22.9% | — | Source |
Tata Motors
| Year | Revenue | Net income | Margin | Growth | Source |
|---|---|---|---|---|---|
| FY2026 | ~$9.7B | ~$351.5M | 3.6% | +44.0% | Source |
| FY2025 | ~$6.8B | ~$370.6M | 5.5% | -26.1% | Source |
| FY2024 | ~$9.1B | — | 0.0% | — | Source |
Where the revenue comes from
Bristol-Myers Squibb
- Growth Portfolio~55%
$26.4 billion in 2025, up 17%: Opdivo, Opdivo Qvantig, Orencia, Yervoy, Reblozyl, Breyanzi, Opdualag, Camzyos, Sotyktu, Cobenfy, Krazati and other newer brands. It grew another 15% to $7.56 billion in the second quarter of 2026.
- Legacy Portfolio~45%
$21.8 billion in 2025: Eliquis ($14.4 billion), Revlimid ($3.0 billion), Pomalyst/Imnovid ($2.7 billion), Sprycel, Abraxane and other mature brands facing generic competition. Legacy revenue fell 4% in the second quarter of 2026.
Tata Motors
- Trucks and small commercial vehicles
Primary revenue source
Revenue from trucks, pickups, small commercial vehicles and heavy vehicles.
- Buses and vans
Major segment
Bus and van sales to public transport, schools, fleets and private operators.
- Spares and services
Recurring support stream
Parts, maintenance, service contracts, uptime products and dealer service revenue.
- Connected and non-vehicular businesses
Strategic growth stream
Fleet Edge, Tata OK, aggregates and other mobility services.
Business model and strategy
Bristol-Myers Squibb
How it makes money
BMS discovers, licenses or buys drug candidates, takes them through clinical trials, and sells approved medicines under patent protection to wholesalers, specialty pharmacies and hospitals. Net product sales were $46.8 billion of the $48.2 billion total in 2025; alliance, royalty and other revenues made up the remaining $1.4 billion, including royalties from Merck on Winrevair.
Growth strategy
BMS is pursuing growth on three fronts. First, scaling the Growth Portfolio (Opdivo Qvantig, Reblozyl, Camzyos, Breyanzi, Opdualag, Cobenfy and others), which rose 17 percent to $26.4 billion in 2025 and 15 percent to $7.56 billion in the second quarter of 2026.
Competitive advantage
BMS's advantage is its expertise in oncology and its large commercial and regulatory organization. Developing a cancer immunotherapy is complex, and winning approval from regulators and getting doctors to prescribe it requires an established global sales and regulatory team.
Tata Motors
How it makes money
Tata Motors -- following an October 2025 demerger that split the historic company in two -- now refers specifically to the commercial-vehicle business: trucks, buses, and other heavy vehicles sold mostly to the Indian domestic market, plus a proposed international expansion through the pending Iveco Group acquisition.
Growth strategy
Tata Motors is growing through next-generation trucks, buses, electric and alternative-fuel commercial vehicles, Fleet Edge, service parts, exports, operational discipline and the planned Iveco expansion.
Competitive advantage
Tata Motors' advantage is its scale in Indian commercial vehicles, deep dealer and service reach, Tata brand trust, engineering base and ability to bundle vehicles, spares, fleet tools and service.
Questions about Bristol-Myers Squibb vs Tata Motors
Which company has higher revenue — Bristol-Myers Squibb Company or Tata Motors Limited?
Bristol-Myers Squibb Company reported $48.2B (FY2025), while Tata Motors Limited reported ~$9.7B (FY2026). By last reported revenue, Bristol-Myers Squibb Company is the larger business, with Tata Motors Limited reporting a smaller revenue base. Note: these are from different fiscal years and are not a direct like-for-like comparison.
What is the market cap of Bristol-Myers Squibb Company vs Tata Motors Limited?
Bristol-Myers Squibb Company's market capitalisation stands at $127.5B, while Tata Motors Limited's is $17.5B. Bristol-Myers Squibb Company carries the higher market valuation, reflecting investors' expectations of its future earnings power relative to Tata Motors Limited.
Which is more financially efficient — Bristol-Myers Squibb Company or Tata Motors Limited?
Bristol-Myers Squibb Company generates $1.48M / employee in revenue per employee, while Tata Motors Limited generates $240k / employee. Bristol-Myers Squibb Company shows higher revenue efficiency per headcount, though this reflects business model differences — capital-light software companies routinely outperform labour-intensive manufacturers on this metric.
How do Bristol-Myers Squibb Company and Tata Motors Limited make money?
Bristol-Myers Squibb Company and Tata Motors Limited generate revenue in fundamentally different ways. Bristol-Myers Squibb Company: BMS discovers, licenses or buys drug candidates, takes them through clinical trials, and sells approved medicines under patent protection to wholesalers, specialty pharmacies and hospitals. Tata Motors Limited: Tata Motors -- following an October 2025 demerger that split the historic company in two -- now refers specifically to the commercial-vehicle business: trucks, buses, and other heavy vehicles sold mostly to the Indian domestic market, plus a proposed international expansion through the pending Iveco Group acquisition.
Which company is valued higher relative to revenue — Bristol-Myers Squibb Company or Tata Motors Limited?
On a price-to-sales (P/S) basis, Bristol-Myers Squibb Company trades at 2.6x P/S and Tata Motors Limited at 1.8x P/S. Bristol-Myers Squibb Company commands a higher revenue multiple, typically indicating that investors expect faster growth or higher future margins compared to Tata Motors Limited. A higher multiple is not inherently better — it may also signal that the stock is priced for perfection.
Is Bristol-Myers Squibb Company bigger than Tata Motors Limited?
By last reported revenue, Bristol-Myers Squibb Company ($48.2B (FY2025)) is the larger company compared to Tata Motors Limited (~$9.7B (FY2026)). Revenue scale is one dimension of size — market capitalisation, employee count, and geographic reach are also relevant depending on the context.
Figures come from each company's filings and the sources linked beside them. Amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Back to the Bristol-Myers Squibb vs Tata Motors overview